EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Emergent BioSolutions Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.36−0.02 (-0.31%)
Close on Oct 19, 2026
- Market cap
- $328.18M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.80 (−30.57%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Emergent BioSolutions Inc. saw revenue fall 9.6% to $770.20M over the twelve months to Jun 30, 2026. Operating income fell 162.0% to -$66.00M, moving the operating margin from 12.5% to -8.6%. Free cash flow was $85.90M, down 44.6% from a year earlier.
Revenue
$770.20M
-9.6% vs. a year earlier
Operating income
-$66.00M
-162.0% vs. a year earlier
Free cash flow
$85.90M
-44.6% vs. a year earlier
EPS, diluted
-$3.47
-241.6% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $328.18M
- P/E ratio
- –
- Price to sales
- 0.43
- Price to book
- 0.96
- Dividend yield
- –
- Free cash flow yield
- 26.17%
Fundamentals
- Revenue
- $770.20M
- Net income
- -$176.80M
- EPS, diluted
- -$3.47
- Free cash flow
- $85.90M
- Book value per share
- $6.62
- Diluted shares
- 52M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$770.20M-9.6% YoY
Gross profit
$430.30M-3.4% YoY
Operating income
-$66.00M-162.0% YoY
Net income
-$176.80M-226.7% YoY
EPS, diluted
-$3.47-241.6% YoY
Free cash flow
$85.90M-44.6% YoY
Reported periodTrailing twelve months